Evidence map›Paper›PMID 37223633›Full record

ArticleUpsala journal of medical sciences2023

Validation of myocarditis diagnoses in the Swedish patient register for analyses of potential adverse reactions to COVID-19 vaccines.

Rolf Gedeborg, Lennart Holm, Nils Feltelius, Anders Sundström, Kai M Eggers, Marja-Leena Nurminen, Maria Grünewald, Nicklas Pihlström, Björn Zethelius, Rickard Ljung

Abstract read
In one paragraph

Article in Upsala journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rolf GedeborgDepartment of Efficacy and Safety 1, Division of Licensing, Medical Products Agency, Uppsala, Sweden.
Lennart HolmOffice of Use and Information, Division of Use and Information, Medical Products Agency, Uppsala, Sweden.
Nils FelteliusOffice of Use and Information, Division of Use and Information, Medical Products Agency, Uppsala, Sweden.
Anders SundströmDepartment of Drug Safety, Division of Use and Information, Medical Products Agency, Uppsala, Sweden.
Kai M EggersDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Marja-Leena NurminenDepartment of Drug Safety, Division of Use and Information, Medical Products Agency, Uppsala, Sweden.
Maria GrünewaldStatistics group, Department of Efficacy and Safety 2, Division of Licensing, Medical Products Agency, Uppsala, Sweden.
Nicklas PihlströmStatistics group, Department of Efficacy and Safety 2, Division of Licensing, Medical Products Agency, Uppsala, Sweden.
Björn ZetheliusOffice of Use and Information, Division of Use and Information, Medical Products Agency, Uppsala, Sweden.
Rickard LjungOffice of Use and Information, Division of Use and Information, Medical Products Agency, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronavirus disease 2019 (COVID-19) mRNA vaccines are associated with an increased risk of myocarditis using hospital discharge diagnoses as an outcome. The validity of these register-based diagnoses is uncertain. Methods: Patient records for subjects < 40 years of age and a diagnosis of myocarditis in the Swedish National Patient Register were manually reviewed. Brighton Collaboration diagnosis criteria for myocarditis were applied based on patient history, clinical examination, laboratory data, electrocardiograms, echocardiography, magnetic resonance imaging and myocardial biopsy. Poisson regression was used to estimate incidence rate ratios, comparing the register-based outcome variable to validated outcomes. Interrater reliability was assessed by a blinded re-evaluation. Results: Overall, 95.6% (327/342) of cases registered as myocarditis were confirmed (definite, probable or possible myocarditis according to Brighton Collaboration diagnosis criteria, positive predictive value 0.96 [95% CI 0.93-0.98]). Of the 4.4% (15/342) cases reclassified as no myocarditis or as insufficient information, two cases had been exposed to the COVID-19 vaccine no more than 28 days before the myocarditis diagnosis, two cases were exposed >28 days before admission and 11 cases were unexposed to the vaccine. The reclassification had only minor impact on incidence rate ratios for myocarditis following COVID-19 vaccination. In total, 51 cases were sampled for a blinded re-evaluation. Of the 30 randomly sampled cases initially classified as either definite or probably myocarditis, none were re-classified after re-evaluation. Of the in all 15 cases initially classified as no myocarditis or insufficient information, 7 were after re-evaluation re-classified as probable or possible myocarditis. This re-classification was mostly due to substantial variability in electrocardiogram interpretation. Conclusion: This validation of register-based diagnoses of myocarditis by manual patient record review confirmed the register diagnosis in 96% of cases and had high interrater reliability. Reclassification had only a minor impact on the incidence rate ratios for myocarditis following COVID-19 vaccination.

Indexed as

COVID-19COVID-19 VaccinesBiopsyHumansReproducibility of ResultsSwedenCOVID-19 VaccinesCOVID-19 vaccinesdiagnosismyocarditisvalidation study

Identifiers

PMID37223633
PMCPMC10202079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.